![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/ASTRAZEN.png)
Share the post "AstraZeneca Pharma India ‘s Q3 2024-25 Latest News: Profit Rises by 95.25% YoY"
Highlights
🔹 The presented financial data is Standalone to provide a comprehensive overview of the company performance. 🔹 Sales over the Year and quarter: The company experienced a substantial growth of 43.98 % in the past year, substantial increase in net sales/revenue by 7.92 %. 🔹 Income over the Year and quarter: There has been decline in other income over the past year which is -364.67 %, Marginal decrease of -413.55% in other income during this quarter. 🔹 Profit over the Year and quarter: Significant improvement in profitability for AstraZeneca Pharma India Limited. Notable increase of 95.25 % in net profit Year to Year, AstraZeneca Pharma India Limited’s profitability dropped by -19.72 % Quarter to Quarter. 🔹 EPS over the Year and quarter: EPS increased by 95.25 % Year to Year. EPS decreased by -19.71 % in previous quarter. Analysis needed for shareholder value.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 305.789 Cr | Rs. 407.996 Cr | Rs. 440.289 Cr | + 7.92 % | + 43.98 % |
| Expenses | Rs. 290.74 Cr | Rs. 355.46 Cr | Rs. 363.3 Cr | + 2.21 % | + 24.96 % |
| Operating Profit | Rs. 15.05 Cr | Rs. 52.54 Cr | Rs. 76.99 Cr | + 46.54 % | + 411.56 % |
| OPM % | 4.92 % | 12.88 % | 17.49 % | + 4.61 % | + 12.57 % |
| Other Income | Rs. 9.66 Cr | Rs. 8.154 Cr | Rs. -25.567 Cr | -413.55 % | -364.67 % |
| Interest | Rs. 0.61 Cr | Rs. 0.34 Cr | Rs. 0.33 Cr | -2.94 % | -45.9 % |
| Depreciation | Rs. 3.71 Cr | Rs. 9.32 Cr | Rs. 9.07 Cr | -2.68 % | + 144.47 % |
| Profit before tax | Rs. 20.39 Cr | Rs. 51.03 Cr | Rs. 42.02 Cr | -17.66 % | + 106.08 % |
| Tax % | 22.54 % | 24.7 % | 26.58 % | + 1.88 % | + 4.04 % |
| Net Profit | Rs. 15.8 Cr | Rs. 38.43 Cr | Rs. 30.85 Cr | -19.72 % | + 95.25 % |
| EPS in Rs | Rs. 6.32 | Rs. 15.37 | Rs. 12.34 | -19.71 % | + 95.25 % |
Today, we’re looking at AstraZeneca Pharma India Limited’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a robust year-over-year sales growth of 43.98 %. However, it did see a marginal increase of 7.92 % from the previous quarter. Expenses ticked up slightly by 2.21 % quarter-on-quarter, aligning with the annual rise of 24.96 %. Operating profit, while up 411.56 % compared to last year, faced a quarter-on-quarter increase of 46.54 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 12.57 %, but an expansion of 4.61 % sequentially. Other income fell by -413.55 % compared to the last quarter, despite an annual decline of -364.67 %. Interest expenses dropped significantly by -2.94 % from the previous quarter, yet the year-over-year decrease remains at a moderate -45.9 %. Depreciation costs fell by -2.68 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 144.47 %. Profit before tax grew annually by 106.08 % but saw a reduction from the preceding quarter by -17.66 %.
Tax expenses as a percentage of profits increased slightly by 4.04 % compared to last year, with a more notable quarter-on-quarter increase of 1.88 %. Net profit rose by 95.25 % year-on-year but witnessed a -19.72 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 95.25 % but a quarterly fall of -19.71 %. In summary, AstraZeneca Pharma India Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 305.789 Cr | Rs. 407.996 Cr | Rs. 440.289 Cr | + 7.92 % | + 43.98 % |
| Expenses | Rs. 290.74 Cr | Rs. 355.46 Cr | Rs. 363.3 Cr | + 2.21 % | + 24.96 % |
| Operating Profit | Rs. 15.05 Cr | Rs. 52.54 Cr | Rs. 76.99 Cr | + 46.54 % | + 411.56 % |
| Net Profit | Rs. 15.8 Cr | Rs. 38.43 Cr | Rs. 30.85 Cr | -19.72 % | + 95.25 % |
| EPS in Rs | Rs. 6.32 | Rs. 15.37 | Rs. 12.34 | -19.71 % | + 95.25 % |
In reviewing AstraZeneca Pharma India Limited’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 43.98 % year-on-year growth, however, there was a minor increase of 7.92 % from the previous quarter. Expenses rose by 24.96 % compared to the previous year, with a 2.21 % increase quarter-on-quarter. Operating Profit surged by 411.56 % annually, and saw a 46.54 % increase from the last quarter.
Net Profit showed yearly increase of 95.25 %, and experienced a -19.72 % decrease from the previous quarter. Earnings Per Share (EPS) rose by 95.25 % annually, however dipped by -19.71 % compared to the last quarter. In essence, while AstraZeneca Pharma India Limited exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/FLUOROCHEM.png)